EGFR and non-small cell lung carcinoma: In this case, we showed that the programmed cell death protein 1 (PD-1) inhibitor toripalimab plus chemotherapy and apatinib was effective and tolerable in a locally advanced <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC) patient with a positive PD-L1 expression.